Sharekhan

Indegene Ltd

Mon 4/05/2026,14:9:57 | NSE : INDGN

₹ 531.2031.45 (6.29%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 505.00

Previous Close

₹ 499.75

Volume

824060

Mkt Cap ( Rs. Cr)

₹12786.85

High

₹ 534.25

Low

₹ 505.00

52 Week High

₹ 632.90

52 Week Low

₹ 414.00

Book Value Per Share

₹ 123.33

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Indegene Ltd

Your Vote -

Buy

80.00%

Hold

0.00%

Sell

20.00%

80.00%

5 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

37%

Sell Order Quantity

63%

Bid Price

Qty

530.50

20

530.00

18

530.00

27

530.00

14

530.00

41

Bid Total

73313

Bid Price

Qty

530.70

1

531.00

12

531.00

27

531.00

9

531.00

52

Bid Total

125856

Option Chain

Analyzes market sentiment, predicts Indegene Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Indegene - Copy of Newspaper Publication

    1 May 2026, 5:44PM Indegene Limited has informed the Exchange about Copy of Newspaper Publication
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    30 Apr 2026, 11:44AM Audio Recording of the Q4 and Annual FY26 Earnings Call
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Apr 2026, 11:44AM Indegene Limited has informed the Exchange about Link of Recording
  • Indegene - Intimation Of Outcome Of Board Meeting

    29 Apr 2026, 9:49PM Outcome of Board Meeting
  • Indegene - General Updates

    29 Apr 2026, 9:40PM Indegene Limited has informed the Exchange about Trading Window opening
  • Indegene - Monitoring Agency Report

    29 Apr 2026, 9:32PM Monitoring Agency Report
  • Indegene - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    29 Apr 2026, 9:30PM Monitoring Agency Report
  • Indegene - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    29 Apr 2026, 9:21PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td
  • Indegene - Allotment of Securities

    29 Apr 2026, 9:06PM Indegene Limited has informed the Exchange regarding allotment of 52951 securities pursuant to ESOP/ESPS at its meeting held on April 29, 2026
  • Indegene - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    29 Apr 2026, 9:04PM Allotment of Shares under ESOP Scheme 2020 and RSU Scheme 2020
  • Indegene - Dividend

    29 Apr 2026, 9:01PM Indegene Limited has informed the Exchange that Board of Directors at its meeting held on April 29, 2026, recommended Final Dividend of Rs. 2.25 per e
  • Indegene - Announcement under Regulation 30 (LODR)-Dividend Updates

    29 Apr 2026, 9:01PM Outcome of Board Meeting
  • Indegene Q4 net profit up 33.03% at Rs 72.10 cr

    29 Apr 2026, 8:50PM The company reported standalone net profit of Rs 72.10 crore for the quarter ended March 31, 2026 as compared to Rs 54.20 crore in the same period las
  • Indegene - Announcement under Regulation 30 (LODR)-Investor Presentation

    29 Apr 2026, 8:49PM Analyst Presentation and fact sheet - financial results for the quarter and year ended March 31, 2026
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Apr 2026, 8:49PM Indegene Limited has informed the Exchange about Presentation
  • Indegene - Press Release

    29 Apr 2026, 8:40PM Indegene Limited has informed the Exchange regarding a press release dated April 29, 2026, titled ""Indegene Reports 32.8% YoY Growth in Q4FY26, Cross
  • Indegene - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    29 Apr 2026, 8:40PM Press Release
  • Indegene - Outcome of Board Meeting

    29 Apr 2026, 8:32PM Outcome of Board Meeting
  • Indegene - Board Meeting Outcome for Outcome Of Board Meeting

    29 Apr 2026, 8:32PM Outcome of Board Meeting
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    22 Apr 2026, 11:38AM Intimation of Indegene Q4 and Annual FY26 Earnings Call
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    22 Apr 2026, 11:38AM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Board Meeting Intimation for Consideration And Approval Of Audited Financial Results Of The Company And Recommenda

    21 Apr 2026, 5:49PM Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2026 ,inter alia, to consider and approve
  • Indegene has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    20 Apr 2026, 4:00PM As of March 2026, 100.00% owned by Public. <p align=justify> Institutional holds 18.56% (Insurance Companies 0.01%) and Non-Institutional holds 81.43%
  • Indegene - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    9 Apr 2026, 3:35PM Indegene Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Indegene - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Apr 2026, 3:37PM Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
  • Indegene - Intimation Of Agreement

    1 Apr 2026, 6:08PM Intimation of Agreement
  • Indegene - Agreements

    1 Apr 2026, 6:04PM Indegene Limited has informed the Exchange about Agreements
  • Indegene - Trading Window

    27 Mar 2026, 11:44AM Indegene Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
  • Indegene - Clarification Letter

    24 Mar 2026, 1:08PM Clarification Letter
  • Indegene - Clarification sought from Indegene Ltd

    24 Mar 2026, 12:14PM The Exchange has sought clarification from Indegene Ltd on March 24, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.
  • Indegene - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    18 Mar 2026, 8:53PM Allotment under RSU Plan 2020
  • Indegene - ESOP/ESOS/ESPS

    18 Mar 2026, 8:52PM Indegene Limited has informed the Exchange regarding Allotment of 93390 Shares.
  • Indegene - Clarification Letter

    16 Mar 2026, 12:56PM Clarification Letter
  • Indegene - Clarification sought from Indegene Ltd

    16 Mar 2026, 11:46AM The Exchange has sought clarification from Indegene Ltd on March 16, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    13 Mar 2026, 3:30PM Intimation of schedule of Investor/ Analyst meeting
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Mar 2026, 3:29PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - General Updates

    12 Mar 2026, 2:36PM Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
  • Indegene - .Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    12 Mar 2026, 2:37PM Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015.
  • Indegene - Acquisition

    1 Mar 2026, 5:33PM Indegene Limited has informed the Exchange about Acquisition
  • Indegene - Announcement under Regulation 30 (LODR)-Acquisition

    1 Mar 2026, 5:30PM Acquisition
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    25 Feb 2026, 7:01PM Intimation of Schedule of Investors / Analysts meetings under SEBI (LODR) Regulations, 2015
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    25 Feb 2026, 7:01PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    20 Feb 2026, 9:38PM Allotment of Share under ESOP/RSU Plan 2020.
  • Indegene - ESOP/ESOS/ESPS

    20 Feb 2026, 9:10PM Indegene Limited has informed the Exchange regarding Allotment of 327880 Shares.
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    16 Feb 2026, 4:51PM Indegene Limited has informed the Exchange about Schedule of meet
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    16 Feb 2026, 5:01PM Intimation of Schedule of Investors/Analysts meeting under SEBI (LODR) Regulations, 2015
  • Indegene - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    9 Feb 2026, 5:17PM Intimation of Schedule of Investors/Analysts meetings Under SEBI (LODR) Regulations, 2015
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    9 Feb 2026, 5:17PM Intimation of Schedule of Investors / Analysts meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015
  • Indegene - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    4 Feb 2026, 6:06PM Transcript of earnings conference call on financial results for the quarter ended December 31, 2025.
  • Indegene - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Feb 2026, 6:06PM Transcript of the earnings conference call on financial results for the quarter ended December 31, 2025
  • Indegene Ltd

    9 Oct 2025 , 9:01AM Indegene : The company is ramping up its US strategy, betting that pricing pressures under the Trump administration will accelerate the pharmaceutical industry’s shift toward digital-first, non-personal marketing. The company’s recent $104 million acquisition of BioPharm Communications, a Pennsylvania-based adtech firm, is central to this pivot. BioPharm acquisition from Omnicom Group gives Indegene access to a proprietary database of more than 15 million physician engagements and around 300 million exposure events, enabling hyper-targeted campaigns for top pharma clients.
  • Indegene Ltd

    4 Jun 2025 , 9:49AM Indegene: Carlyle Group is set to exit a 10.2% stake in the company for at least Rs 1,420 crore. The floor price is Rs 580 per share, which is a 6% discount from the current market price.
  • Indegene

    20 Mar 2025 , 11:34AM The company launched a new centre In London to expand in Europe. This aligns with the company's long-term growth strategy in Europe, reiterating its commitment to enable life sciences clients in the region to be future-ready.
  • Indegene

    3 Dec 2024 , 11:16AM Global private equity firm Carlyle-backed CA Dawn Investments likely to divest 2.9% stake in Indegene via block deal at Rs.615 per share. As per media sources, the sale could raise approximately Rs 470 crore, based on the offered floor price.
  • Indegene announces strategic collaboration with Microsoft

    11 Jul 2024 , 11:38AM Indegene collaborates with Microsoft to help life sciences companies scale up Generative AI adoption

Key fundamentals

Evaluate the intrinsic value of Indegene Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 1888.2 953.8 795.3 650 442.2
Liabilities 1888.2 953.8 795.3 650 442.2
Equity 47.9 44.4 44.3 0.4 0.3
Gross Profit 180.5 168 177.9 168.7 150.4
Net Profit 181.3 137.9 130.2 132.7 133.4
Cash From Operating Activities 129 176.2 81.9 38.2 54.6
NPM(%) 16.57 13.18 12.94 15.85 26.1
Revenue 1093.6 1045.6 1005.7 836.7 511
Expenses 913.1 877.6 827.8 668 360.6
ROE(%) 6.1 4.64 4.38 4.47 4.49

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
2.25 112.5 0 495.45
13 Jun 2025 2 100 0 571.5

Peers

Other companies within the same industry or sector that are comparable to Indegene Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Visagar Polytex Ltd 0.58 3.57 0.00 14621.88 -5.68 0.00
India Motor Parts and Accessories Ltd 1020.00 1.58 14.63 623.44 670.43 2.94
Madhya Pradesh Today Media Ltd 44.00 3.53 5.77 228.19 69.80 0.00
Hathway Cable and Datacom Ltd 10.96 -0.45 23.83 88425.35 23.25 0.00

Company Info

Our Company was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of our Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by our Shareholders at the EGM held on February 29, 2016, the name of our Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of our Company was changed to better reflect the nature of business undertaken by our Company. Thereafter, the registered office of our Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on November 7, 2022 and the name of our Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to our Company by the RoC, on November 17, 2022.Major events and milestones:2005-Raised funding from Nadathur Holdings & Investments Private Limited-Expanded operations to the USA by incorporating a subsidiary named Indegene, Inc.-Expanded operations to Southeast Asia by incorporating a subsidiary named Indegene Fareast Pte. Ltd. in Singapore2006-Acquisition of Medsn, Inc.1 a company in the USA which is engaged in medical education and marketing business, by one of our Material Subsidiaries, Indegene, Inc.2 through the merger of Medsn Merger Sub, Inc., an erstwhile wholly owned subsidiary of Indegene, Inc. with Medsn, Inc.2007-Expanded our services to include European territory2008-Received BS ISO/IEC 27001:2005 certification for information security management system32009-Received ISO 9001:2000 certification for quality management system42012-Expanded operations to China by incorporating a subsidiary named Indegene Lifesystems Consulting (Shanghai) Co., Ltd.2017-Acquisition of the Encima Group, Inc., a corporation which operates a digital service, marketing automation and analytics services business supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.2020-Acquisition of DT Associates Research and Consulting Services Limited, a consulting services company in UK supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.-Launched Indegene Digital Summit, a symposium on digital transformation and customer experience in life sciences2021-Expanded operations to Japan by incorporating a subsidiary named Indegene Japan, LLC-Raised equity funding from CA Dawn Investments and Brighton Park Capital-Received BS ISO/IEC 27701:2019 certification for privacy information management system52022-Acquisition of Medical Marketing Economics, LLC by one of our Material Subsidiaries, ILSL Holdings, Inc. and subsequent merger of Medical Marketing Economics, LLC with Indegene, Inc.-Expanded global operations with new offices in Mexico2023-Acquisition of Cult Health, a company engaged in the business of providing advertising services to parties in the healthcare sector, by one of our Material Subsidiaries, ILSL Holdings, Inc.-Expanded our presence in Europe with the acquisition of Indegene Healthcare Germany GmbH (formerly Sotus 852 GmbH) by our subsidiary, Indegene Ireland Limited-Launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform2024-Acquisition of Trilogy Writing & Consulting GmbH, a company engaged in providing high-end medical writing to customers that include market-leading pharmaceutical companies, along with three of its wholly owned subsidiaries, by one of our Subsidiaries, Indegene Ireland Limited.-Ranked 167 in The Next 500 India's Largest Emerging Companies by Fortune India.2025-Deloitte Names Indegene a Winner of Enterprise Growth Awards 2025.-"Indegene Wins BIG Innovation Award_January 2025."-Indegene Acquired BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma.-Everest Group Recognized Indegene as a Leader in Life Sciences AI and Analytics for Commercial PEAK Matrix Assessment 2025.-Indegene Launched NEXT Medical Writing Automation to Streamline Complex Medical Writing Workflows with GenAI.-Indegene Launched Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry.

Our Company was incorporated as `Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 16, 1998, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli at Ahmedabad. Thereafter, the registered office of our Company was shifted from Gujarat to Karnataka in June 2003, and then, from Karnataka to Maharashtra in May 2014. Further, pursuant to a resolution passed by our Shareholders at the EGM held on February 29, 2016, the name of our Company was changed to `Indegene Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. The name of our Company was changed to better reflect the nature of business undertaken by our Company. Thereafter, the registered office of our Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on November 7, 2022 and the name of our Company was changed to `Indegene Limited' and a fresh certificate of incorporation was issued to our Company by the RoC, on November 17, 2022.Major events and milestones:2005-Raised funding from Nadathur Holdings & Investments Private Limited-Expanded operations to the USA by incorporating a subsidiary named Indegene, Inc.-Expanded operations to Southeast Asia by incorporating a subsidiary named Indegene Fareast Pte. Ltd. in Singapore2006-Acquisition of Medsn, Inc.1 a company in the USA which is engaged in medical education and marketing business, by one of our Material Subsidiaries, Indegene, Inc.2 through the merger of Medsn Merger Sub, Inc., an erstwhile wholly owned subsidiary of Indegene, Inc. with Medsn, Inc.2007-Expanded our services to include European territory2008-Received BS ISO/IEC 27001:2005 certification for information security management system32009-Received ISO 9001:2000 certification for quality management system42012-Expanded operations to China by incorporating a subsidiary named Indegene Lifesystems Consulting (Shanghai) Co., Ltd.2017-Acquisition of the Encima Group, Inc., a corporation which operates a digital service, marketing automation and analytics services business supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.2020-Acquisition of DT Associates Research and Consulting Services Limited, a consulting services company in UK supporting clients in healthcare, life sciences and other industries by one of our Material Subsidiaries, ILSL Holdings, Inc.-Launched Indegene Digital Summit, a symposium on digital transformation and customer experience in life sciences2021-Expanded operations to Japan by incorporating a subsidiary named Indegene Japan, LLC-Raised equity funding from CA Dawn Investments and Brighton Park Capital-Received BS ISO/IEC 27701:2019 certification for privacy information management system52022-Acquisition of Medical Marketing Economics, LLC by one of our Material Subsidiaries, ILSL Holdings, Inc. and subsequent merger of Medical Marketing Economics, LLC with Indegene, Inc.-Expanded global operations with new offices in Mexico2023-Acquisition of Cult Health, a company engaged in the business of providing advertising services to parties in the healthcare sector, by one of our Material Subsidiaries, ILSL Holdings, Inc.-Expanded our presence in Europe with the acquisition of Indegene Healthcare Germany GmbH (formerly Sotus 852 GmbH) by our subsidiary, Indegene Ireland Limited-Launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform2024-Acquisition of Trilogy Writing & Consulting GmbH, a company engaged in providing high-end medical writing to customers that include market-leading pharmaceutical companies, along with three of its wholly owned subsidiaries, by one of our Subsidiaries, Indegene Ireland Limited.-Ranked 167 in The Next 500 India's Largest Emerging Companies by Fortune India.2025-Deloitte Names Indegene a Winner of Enterprise Growth Awards 2025.-"Indegene Wins BIG Innovation Award_January 2025."-Indegene Acquired BioPharm to Expand AI-Driven Marketing and AdTech for Global Pharma.-Everest Group Recognized Indegene as a Leader in Life Sciences AI and Analytics for Commercial PEAK Matrix Assessment 2025.-Indegene Launched NEXT Medical Writing Automation to Streamline Complex Medical Writing Workflows with GenAI.-Indegene Launched Cortex, A Fit-For-Purpose Generative AI Platform, Verticalized For The Life Sciences Industry.

Read More

Parent Organisation

Indegene Ltd.

Founded

16/10/1998

Managing Director

Mr.Manish Gupta

NSE Symbol

INDGNEQ

FAQ

The current price of Indegene Ltd is ₹ 531.20.

The 52-week high for Indegene Ltd is ₹ 534.25 and the 52-week low is ₹ 505.00.

The market capitalization of Indegene Ltd is currently ₹ 12786.85. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Indegene Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Indegene Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Indegene Ltd shares.

The CEO of Indegene Ltd is Mr.Manish Gupta, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT